Estimated Success Rate
0%
Based on clinical evidence from treatment studies
Hyperprolactinaemia is a hormonal disorder where the pituitary gland releases too much prolactin, leading to irregular periods, infertility, unwanted breast milk, and sometimes vision problems.
The condition can stem from a tiny tumour called a pituitary adenoma, certain medications (antipsychotics, anti‑emetics), hypothyroidism, or even stress. When prolactin stays high, the hypothalamic‑pituitary‑gonadal axis gets disrupted, which explains the reproductive symptoms.
Why treat it? Persistent elevation raises the risk of osteoporosis, chronic infertility, and in rare cases, can press on the optic chiasm, causing visual field defects.
All approved drugs belong to the dopamine agonist class. They mimic dopamine’s inhibitory effect on prolactin secretion.
Bromocriptine was the first oral agent. Typical dosing starts at 1.25mg daily, titrated up to 5mg three times a day. It normalizes prolactin in 60‑70% of cases, but the multiple daily doses can cause nausea and fatigue.
Cabergoline is now the preferred first‑line drug because of its longer half‑life. A common regimen is 0.25‑0.5mg twice weekly, sometimes extending to 1mg per week for resistant cases. Clinical trials show >85% success in restoring normal menstrual cycles and fertility, with fewer gastrointestinal side‑effects than bromocriptine.
Quinagolide is taken once daily, starting at 50µg and increasing to 300µg. It offers an alternative for patients who cannot tolerate the other two, though long‑term data are more limited.
About 10‑15% of patients either don’t respond adequately or develop intolerable side‑effects. In those scenarios, surgical removal of the tumour becomes the next logical step.
Transsphenoidal surgery accesses the pituitary through the nose and sphenoid sinus, avoiding a brain craniotomy. The procedure is usually done under general anaesthesia and lasts 2‑3hours.
Success rates depend on tumour size: microadenomas (<10mm) have a cure rate of 90‑95%, while macroadenomas (10‑40mm) drop to 70‑80%. Post‑op complications are rare but can include temporary diabetes insipidus, CSF leak, or nasal congestion.
Decision factors include:
After starting a dopamine agonist, check prolactin level at 4‑6weeks, then every 6‑12months. MRI scans are recommended at baseline and if symptoms worsen.
Common side‑effects:
For surgical patients, a post‑op endocrine clinic follow‑up within 2weeks checks for hormone deficits and confirms tumour removal via MRI.
Drug | Typical Dose | Success Rate | Common Side‑effects | Convenience |
---|---|---|---|---|
Bromocriptine | 1.25‑5mg 3×/day | 60‑70% | Nausea, fatigue | Multiple daily doses |
Cabergoline | 0.25‑1mg twice weekly | 85‑90% | Headache, dizziness | Twice‑weekly, easy |
Quinagolide | 50‑300µg daily | ~70% | GI upset, rash | Once daily |
Rarely. Most cases are linked to a tumour or a persistent physiological trigger, so medication or surgery is needed to bring prolactin back to normal.
Studies show low‑dose cabergoline does not increase birth defects. Many clinicians keep women on the lowest effective dose until conception, then pause the medication under specialist guidance.
Most patients see a dramatic drop within 24‑48hours. Full hormonal stabilization is usually confirmed at the 6‑week post‑op visit.
Chronic high prolactin can lead to bone density loss, persistent infertility, and, if the tumour grows, possible vision loss from optic chiasm compression.
If medication fully controls prolactin and the tumour is small, yearly MRI is often unnecessary. However, any rise in prolactin or new symptoms warrants repeat imaging.
Nikita Warner
October 12, 2025 AT 04:29Hyperprolactinaemia is most often managed initially with dopamine agonists such as cabergoline or bromocriptine, which suppress prolactin secretion in the majority of patients. Cabergoline’s twice‑weekly dosing schedule tends to be better tolerated, while bromocriptine may require multiple daily doses and can cause nausea. If medication fails to normalize prolactin levels after an adequate trial, or if the adenoma is large enough to cause visual field defects, transsphenoidal surgery becomes the next logical step. Regular follow‑up includes serum prolactin measurements and periodic MRI to monitor tumour size. The choice between medical and surgical therapy should be individualized based on tumour characteristics, side‑effect profile, and patient preference.
Liam Mahoney
October 13, 2025 AT 04:46Honestly, people who ignore the importance of adherence to dopamine agonist therapy are just asking for trouble; you cant expect miracles if you skip doses or quit because of a little nausea. The meds are proven, the data is solid, and the side‑effects are manageable with proper titration. Stop making excuses and talk to your endocrinologist about dose adjustments instead of throwing away a proven treatment. It's morally irresponsible to disregard such a simple, life‑changing intervention.